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Abstract: As a result of the association of a common polymorphism (rs2231142, Q141K) in the 
ATP-binding cassette G2 (ABCG2) transporter with serum urate concentration in a genome-wide 
association study, it was revealed that ABCG2 is an important uric acid transporter. This review 
discusses the relevance of ABCG2 polymorphisms in gout, possible etiological mechanisms, 
and treatment approaches. The 141K ABCG2 urate-increasing variant causes instability in the 
nucleotide-binding domain, leading to decreased surface expression and function. Trafficking of 
the protein to the cell membrane is altered, and instead, there is an increased ubiquitin-mediated 
proteasomal degradation of the variant protein as well as sequestration into aggresomes. In 
humans, this leads to decreased uric acid excretion through both the kidney and the gut with 
the potential for a subsequent compensatory increase in renal urinary excretion. Not only does 
the 141K polymorphism in ABCG2 lead to hyperuricemia through renal overload and renal 
underexcretion, but emerging evidence indicates that it also increases the risk of acute gout 
in the presence of hyperuricemia, early onset of gout, tophi formation, and a poor response to 
allopurinol. In addition, there is some evidence that ABCG2 dysfunction may promote renal 
dysfunction in chronic kidney disease patients, increase systemic inflammatory responses, 
and decrease cellular autophagic responses to stress. These results suggest multiple benefits in 
restoring ABCG2 function. It has been shown that decreased ABCG2 141K surface expression 
and function can be restored with colchicine and other small molecule correctors. However, 
caution should be exercised in any application of these approaches given the role of surface 
ABCG2 in drug resistance.
Keywords: ABCG2, BCRP, gout, urate, uric acid, polymorphism, allopurinol
Introduction
Gout is an inflammatory arthritis caused by an extremely painful but self-limiting innate 
immune response to monosodium urate (MSU) crystals deposited in synovial fluid.1 
Without effective management, in some individuals, gout can become chronic with 
the development of tophi (organized lumps of urate and immune cells2) and permanent 
bony erosion and disability. Gout is also comorbid with other metabolic-based condi-
tions such as heart and kidney disease and type 2 diabetes.3 An elevated concentration 
of urate (hyperuricemia) is necessary, but not sufficient, for the development of gout. 
Host-specific and environmental factors are required for the progression from hyper-
uricemia to gout. Approximately 30 genetic loci, including ABCG2, influence serum 
urate concentrations,4 but less is understood about the genetic control of the formation 
of MSU crystals and the subsequent inflammatory response.5 Urate-lowering therapy 
is a cornerstone of gout management; however, for various reasons, it is often not 
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effective.1 Despite the availability of a range of cost-effective 
urate-lowering drugs, there is a need for the development of 
better therapies for acute gout.
The ATP-binding cassette G2 (ABCG2) protein first came 
to biomedical attention through its contribution to an ATP-
dependent multidrug resistance phenotype in a breast cancer 
cell line.6 It is one of a superfamily of 48 human ABC trans-
porters that, in general, transport a wide array of substrates 
and are dependent on ATP binding to activate transport. The 
ABCG2 transporter is one of three well-studied multidrug 
transporters (others are multidrug resistance protein 1 and 
P-glycoprotein encoded by the ABCC1 and ABCB1 genes, 
respectively). These transporters export a wide range of 
compounds, including in the case of ABCG2, uric acid from 
cells. ABCG2 is a “half transporter” ABC protein, contain-
ing one membrane-spanning domain of six transmembrane 
helices, a N-terminal single intracellular portion containing 
a nucleotide-binding domain (NBD), and a short intracellular 
C-terminal tail (Figure 1). “Half transporters” like ABCG2 
need to homodimerize to function in vitro but more likely 
exist in higher-order tetrameric or greater assemblages.7,8
ABCG2, also known as breast cancer resistance protein, 
is overexpressed in human and animal cell lines resistant to 
chemotherapeutic drugs9,10 and transports anticancer drugs 
such as mitoxantrone and doxorubicin6 (reviewed in refer-
ence 11). ABCG2 is important in stem cell biology.12,13 Also, 
the wide expression pattern in normal tissues (Figure 2) 
suggests that ABCG2 may fill an important physiological 
role as an excretor of environmental and endogenous tox-
ins, for example, heme.14 This assertion is supported by the 
susceptibility of ABCG2 knockout mice to diet-induced pho-
totoxicity and protoporphyria.15 It is expressed in the small 
intestine (excretion and limiting absorption), blood–brain 
and blood–placental barriers (mediating distribution), liver 
and kidney (elimination and excretion), and mammary gland 
(transporting into milk).16 The pattern of ABCG2 expression 
is consistent with its role as a uric acid efflux transporter 
(reviewed in reference 17).
Figure 1 Schematic representation of gout- and hyperuricemia-related polymorphisms in ABCG2. The ABCG2 protein consists of 655 amino acids and can be divided into 
an intracellular N-terminal domain, a nucleotide binding domain, six transmembrane domains, and a C-terminal end. The nucleotide-binding domain (amino acids 44-288) 
contains several signature sequences, named Walker A (A), Walker B (B), and the ABC signature sequence (C). The beginning and end amino acid position numbers are given 
for the signature sequences and the transmembrane domains. The third extracellular loop contains two cysteine residues connected by a disulfide bridge, and a glycosylated 
asparagine residue, both of which influence stability of the receptor. The cysteine residue at position 603 is important for homodimer formation. The V12M polymorphism is 
located in the N-terminal domain. The Q126X and Q141K polymorphisms are both located in the nucleotide-binding domain between the Walker A and the ABC signature 
sequences. 
Abbreviation: ABCG2, ATP-binding cassette G2.
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The ABCG2 transporter was identified as a uric acid 
efflux transporter only after it was associated with serum 
urate concentrations in a large genome-wide association 
study.18,19 This review explores the effects of several poly-
morphisms in the ABCG2 gene on susceptibility to hyper-
uricemia, gout, and chronic kidney disease. Furthermore, the 
role of ABCG2 in inflammatory responses and the possibility 
of ABCG2 as a treatment target are discussed. 
Major ABCG2 genetic variants
The ABCG2 transporter, expressed on erythrocytes, is the 
basis of a recently explained blood group system, Junior 
(Jr).20,21 Individuals null for ABCG2 produce an ABCG2 
alloantibody upon blood transfusion that can cause transfu-
sion reactions, in extreme cases leading to fatal hemolytic 
disease of the fetus and newborn. The Jr(a-) phenotype is 
most prevalent in Japan with the most common Jr(a-) muta-
tions being Q126X (Japanese) and R246K (Europeans).19,20 
There are only two common (≥1%) missense genetic 
variants in the ABCG2 gene (V12M; rs2231137 and 
Q141K; rs2231142) and one common nonsense variant 
(Q126X; rs72552713) that is specific to South East Asian 
populations (Figure 1). The Q141K and Q126X variants 
 influence  expression levels of ABCG2 and contribute risk to 
 phenotypes such as serum urate levels, gout, and response 
to the urate-lowering drug allopurinol (Table 1). Numerous 
other rare (<1%) variants are identified (http://www.ensembl.
org), some of which have been phenotyped.22–28 The most 
widely studied variant is Q141K, a variant that is clinically 
relevant and has significant impact on ABCG2 characteristics. 
It is prevalent in most major population groups with the 141K 
allele frequency varying between 1% in African and 29% in 
South East Asian populations. There is consistent evidence 
for the 141K variant reducing the amount of ABCG2 protein 
expressed both in vitro19,22–25,28,29 and, in vivo, from human 
liver samples.30
Residue 141 is located in the E-helix31 of the NBD of 
ABCG2, an area critical for the packing of the soluble portion 
of the protein. The 141K variant reduces ATPase activity,26,27 
uric acid transport activity, and total and surface abundance 
(Table 1 and Figure 3A). These defects are believed to be 
caused by reduced NBD stability.32 Although proteolysis and 
thermo-stability as assessed by melting point curves of the 
isolated 141K NBD showed only small differences from the 
wild type,33 work done on the whole protein shows evidence 
of increased NBD instability in mammalian expression 
50
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Figure 2 Tissue expression of ABCG2 in humans. Generated from the Genotype Tissue Expression (GTeX) database, derived from deceased people (organ and tissue 
donors) and surgical donors.
Abbreviations: ABCG2, ATP-binding cassette G2; RPKM, reads per kilobase of exon per million reads mapped.
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systems. Stabilizing the 141K variant protein with either 
suppressor mutations or with small molecules that may bind 
the NBD directly34 rescues the trafficking, function, and 
abundance of 141K ABCG2.32 Furthermore, recent model-
ing of the 141K NBD suggested that a loop adjacent to the 
Q141K substitution seems to be shifted outward, caused by 
a potential clash with a histidine residue (H155) at the top of 
the loop. This potential packing error in the NBD seems to be 
corrected by a H155A substitution on the 141K background 
as evidenced by rescued protein abundance.35 The decreased 
NBD stability of the 141K variant increases the interaction 
of the protein with the endoplasmic reticulum-associated 
degradation pathway and subsequent ubiquitin-mediated 
proteasomal degradation.29 There is also strong evidence 
that the 141K variant protein may accumulate in aggresomes 
prior to its degradation.36 In addition, protein expression is 
also influenced by microRNAs (37 and references therein). 
In one example, the 3’ untranslated region truncation 
allows increased expression of ABCG2, removing an hsa-
miR-519c binding site that blocks translation.38 The 141K 
variant enhances the hsa-miR-519c-mediated repression of 
translation.37 Interestingly, the ABCG2 F142 residue is in an 
analogous position to the ∆F508 cystic fibrosis-causing muta-
tion in the cystic fibrosis transmembrane receptor (encoded 
by ABCC7).32 In vitro deletion of F142 from ABCG2 leads 
to major processing and folding defects with no surface 
expression,32,33 marking the Q141 and F142 regions as a more 
general ABC transporter mutational “hot spot.” 
Regulation of ABCG2 expression
The expression of ABCG2 is regulated by several transcrip-
tion factors and hormones. A large number of cis-regulatory 
regions have been identified in or near the promoter region 
of ABCG2 (reviewed in 39). Hypoxia-inducible factor-1 
(HIF-1α) stabilizes under hypoxic conditions and has been 
found to bind to a hypoxia-responsive element in the ABCG2 
promoter and increase expression.40,41 Upstream of HIF-1α, 
signaling via phosphatase and tensin homolog (PTEN), 
phosphoinositide 3-kinase (PI3K) and protein B kinase (Akt) 
regulates ABCG2 expression on the cell membrane.42–45 
Furthermore, nuclear factor E2-related factor 2 (Nrf2), a 
transcription factor involved in activating oxidative stress 
responses, can induce ABCG2 transcription46 in addition to 
inducing the expression of peroxisome proliferator-activated 
receptor gamma (PPARγ).47,48 Finally, the hormone estrogen 
has been found to up-regulate ABCG2 gene expression.49–51 
To our knowledge, however, no polymorphisms in any of 
these regulatory genes have been associated with serum urate T
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levels or gout. However a variant in PPARGC1B (rs45520937) 
has been associated with gout in Han Chinese.52 PPARGC1B 
encodes the PGC1β transcriptional repressor, a coactivator 
for PPARγ that is involved in estrogen signaling53,54 in addi-
tion to a key role in maintaining mitochondrial biogenesis.55 
However the association of PPARGC1B with gout has not 
yet been replicated and it is unknown if rs45520937 is itself 
associated with ABCG2 expression. Since reduced mito-
chondrial DNA copy number is associated with gout56 it is 
possible that systematically linked changes in PGC1β and 
associated molecules (including perhaps ABCG2) are factors 
connecting mitochondrial dysfunction and gout.57
ABCG2, urate control, and risk 
of gout
An individual’s serum urate level, like other complex traits, 
is a function of a suite of inherited genetic variants and 
environmental exposures.5 A genome-wide association study 
identified the Q141K variant in the ABCG2 gene as associ-
ated with serum urate concentration in people of European 
ancestry, with the 141K allele associated with increased 
urate concentration.18 This genome-wide significant level 
of association has been consistently replicated in other 
 genome-wide association studies in people of European and 
east Asian ancestry4,58 but not in people of African–American 
ancestry.59,60 Lack of association in African–Americans in 
GWAS is likely because of the reduced power because of 
lower allele frequency in African–Americans (≤3%) – there 
is nominal evidence for the association of the 141K variant 
with increased serum urate levels in African–Americans18 
and the increased risk of gout.19 The Q141K variant (and 
other variants) has been associated with serum urate levels 
or hyperuricemia in other populations, for example, Tibetan61 
and Korean.62 Uric acid transport assays in Xenopus oocytes 
showed that ABCG2 transports uric acid with the 141K 
variant causing ~50% reduced ability to secrete uric acid.19 
The regulation of ABCG2 protein in epithelial cells is 
largely unknown. However, similar to other uric acid renal 
influx transporters, ABCG2 co-immunoprecipitates with the 
scaffold protein PDZK1,63 suggesting a possible common 
regulatory pathway. 
The magnitude of association of Q141K with serum urate 
levels is the second strongest genome-wide behind SLC2A9, 
which is consistently the strongest in Europeans and East 
Figure 3 Schematic overview of the roles of ABCG2 in hyperuricemia and gout. (A) The ABCG2 transporter is highly expressed in the gut, where it regulates ATP-dependent 
uric acid excretion. The 141K ABCG2 variant leads to decreased surface expression, targeting of the misfolded protein to aggresomes and proteasomal degradation. In 
addition, the polymorphism increases miRNA-mediated degradation of mRNA. The resulting increase in circulating urate not only increases the risk of gout but can also 
induce a more pro-inflammatory state in monocytes due to epigenetic reprogramming.129 Colchicine and HDAC inhibitors (HDACi) can restore 141K surface expression 
and function. (B) Monosodium urate crystals can induce mitochondrial damage, leading to the release of mitochondrial reactive oxygen species and DNA (mtROS, mtDNA), 
which in turn can activate the NLRP3 inflammasome. This can be limited through autophagy-mediated clearance of damaged mitochondria. ABCG2 plays a role in this process. 
In defective or diminished autophagy, p62 can accumulate, bind to keap-1, and induce translocation of Nrf2 to the nucleus. Nrf2 induces transcription of heme oxygenase-1 
and superoxide dismutase (HO-1, SOD), which can also induce NLRP3 inflammasome activation.
Abbreviations: MSU, monosodium urate; HDACi, histone deacetylase inhibitors; TLR, Toll-like receptor; NLRP3, NBD, leucine-rich family [NLR], pyrin containing 3; 
ABCG2, ATP-binding cassette G2; IL, interleukin.
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Asians. Each copy of the 141K allele associates with a 0.22 
mg/dL increase in serum urate in Europeans4 and an 0.14 mg/
dL increase in east Asians.58 The magnitude is stronger in men 
than women and is modulated by body mass index (BMI), 
with the magnitude being stronger in lean people than those 
who are overweight and obese. The sex difference is most 
marked in lean people.64 The sex difference in association 
with serum urate levels is an interesting observation given 
the regulation of ABCG2 expression by estrogen.49–51 Com-
pared to other typical genetic variants controlling complex 
phenotypes, Q141K has a very large magnitude of associa-
tion, explaining ~1% of variance in serum urate levels. This 
compares with ~0.3% for the strongest genetic association 
with BMI at the FTO/IRX3 locus.65 
When associations of other SNPs within the ABCG2 
locus with serum urate levels are tested conditionally on 
Q141K genotype, there is evidence for a second independent 
association at the ABCG2 locus, marked by intronic SNP 
rs2622629.66 This second association is of clinical relevance 
as the rs2622629-correlated SNPs (ie those SNPs in linkage 
disequilibrium) include rs10011796 (r2=0.84 in Europeans). 
Rs10011796 is also implicated in gout and in allopurinol 
response (Table 1).67 The molecular mechanism whereby 
rs2622629 (or tightly correlated variants) influence serum 
urate levels is not known. However, it maps within a DNa-
seI hypersensitivity cluster of ~150 bp (genome.ucsc.edu) 
identified by the Encode project (www.encodeproject.org) 
consistent with the effect of the association being mediated 
through the control of gene expression and/or mRNA edit-
ing. Interestingly, Q141K was not associated with gout in a 
Han Chinese study of 143 patients,68 whereas other variants 
in ABCG2 were, further supporting the existence of multiple 
gout-associated variants in ABCG2.
Aside from Q141K, the only other common (>1%) 
missense variant in ABCG2 is V12M situated in a short 
N-terminal section of ABCG2 prior to the structurally well-
defined NBD (Figure 3). This variant is genetically indepen-
dent of both Q141K (r2=0.002 in Europeans) and rs2622629 
(r2=0.009 in Europeans). However, the impact on ABCG2 
characteristics are, compared to Q141K, very moderate 
and inconsistent (Table 1). There are some data on associa-
tion with serum urate and gout, suggesting an independent 
role for V12M in urate control and risk of gout (given the 
genetic independence from Q141K and rs2622629). Hence, 
V12M can be considered a third independent effect on gout 
in ABCG2, after Q141K and rs10011796/rs2622629. The 
largest genome-wide association study in serum urate in 
Europeans reported an increase in serum urate of 0.077 mg/
dL4 and in East Asians an increase of 0.108 mg/dL58 per copy 
of the 12V allele. In gout, the common 12V allele consis-
tently confers risk in five separate samples drawn from four 
ancestral groups: Europeans within the UK Biobank (odds 
ratio [OR] =1.24 [T Merriman, unpublished data, October 
2016]), Taiwanese Aborigines (OR =1.36),69 Han Chinese in 
Taiwan (OR =1.33),69 Han Chinese in Shanghai (OR =1.82),70 
and New Zealand Māori and Pacific (Polynesian) (OR =1.31 
[T Merriman, unpublished data, October 2016]). Any impact 
of this variant on the uric acid transport activity of ABCG2 
is currently unknown. A combined meta-analysis is shown in 
Figure 4. Based on the impact of the V12M variant on ABCG2 
characteristics (Table 1), it is not obvious how the 12V allele 
increases serum urate levels and risk of gout. It is possible that 
Figure 4 Meta-analysis of association of ABCG2 V12M (rs2231137) with gout: Han Chinese (China),70 Han Chinese (Taiwan),69 Taiwanese Aboriginal,69 New Zealand 
Polynesian (982 cases and 941 controls), and the UK Biobank (2,422 cases and 152,249 controls). Effect is shown to the minor allele (12M). Variant rs4148153 is a surrogate 
marker for rs2231137 in people of Polynesian ancestry. 
Abbreviations: ABCG2, ATP-binding cassette G2; OR, odds ratio; CI, confidence interval; Std, standard.
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0.0837
0.1282
0.0977
0.0933
0.5 1
Beta value
2
–0.304
–0.599
–0.274
–0.217
Std error OR
0.750 [0.592; 0.950] 13.9%
29.0%
12.4%
21.3%
23.4%
100%
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the V12M variant is itself not causal and in genetic correla-
tion (linkage disequilibrium) with a separate causal variant 
(which is not Q141K or rs10011796/rs2622629). 
The kidney is the major regulator of serum urate levels, 
which are determined by the balance of secretion and reab-
sorption. This is controlled by reuptake transporters such 
as GLUT9 (SLC2A9) and URAT1 (SLC22A12) and secre-
tory transporters ABCG271 and NPT1/NPT4 (SLC17A1, 
SLC17A3),72 all of which are genetically associated with 
serum urate concentration.4 Expression of most of these 
transporters is relatively high in the kidney or, for URAT1, 
restricted to the kidney. However, expression of ABCG2 is 
also relatively high in the gut (Figure 2).71 Recent work in a 
Japanese gout cohort has demonstrated the role of ABCG2 
in uric acid excretion in both the gut and kidney. In this 
well-defined Japanese population sample, it was possible to 
create grades of ABCG2 dysfunction based on Q141K and 
Q126X genotype combinations. Individuals positive for the 
dysfunctional variants 126X and 141K had the highest serum 
urate levels and highest risk for gout, and those homozygous 
for 141Q and 126Q had the lowest serum urate levels and 
lowest risk for gout.73 ABCG2 dysfunction has been shown 
to influence extra-renal excretion by correlating with an 
increase in total urinary uric acid excretion. This results in a 
renal overload (ROL) type of hyperuricemia.74 The presence 
of 141K (and 126X) alleles reduces excretion through the 
gut and adds to the circulating urate, overloading the kidney 
excretion system, resulting in increased urinary uric acid 
levels. Further study also revealed that ABCG2 dysfunction 
resulted in a renal under-excretion (RUE) type of hyperuri-
cemia consistent with a critical role in ABCG2-mediated 
uric acid secretion in the kidney.75 Other studies support a 
primary role for ABCG2 in excretion of uric acid by the gut. 
A Spanish study demonstrated considerably stronger asso-
ciation of the 141K allele with gout in patients classified as 
normo-excretors than in those classified as under-excretors,76 
and two New Zealand studies demonstrated 141K-positive 
individuals not to be renal under-excretors of uric acid.77,78 
Predictably, therefore, ABCG2 Q141K associates with 
gout in most, but not all, ancestral groups analyzed – Euro-
pean, Han Chinese, Japanese, Korean, African American, 
Taiwanese Aborigine, and Pacific Islanders but not New 
Zealand Māori.69,79–84 The 126X variant, specific to East 
Asian populations, confers a higher risk to gout than 141K 
in Han Chinese and Japanese sample sets.73 In the context 
that the magnitude of association of ABCG2 on serum urate 
concentration is less than that of SLC2A9,4 it is interesting 
that the magnitude of association of ABCG2 Q141K on the 
risk of gout is consistently larger than that of SLC2A9.4,5,85 
This does not equate with the hypothesis that ABCG2 influ-
ences gout solely through contributing to hyperuricemia. 
Emerging evidence (described in the ‘ABCG2: a regulator 
of gouty inflammation?’ section) indicates that ABCG2 has 
pleiotropic effects in gout, contributing to the etiology of 
gout in the presence of hyperuricemia.  
ABCG2: a regulator of acute gouty 
inflammation?
The key initial checkpoint in gout is hyperuricemia.1 Further 
checkpoints are formation of MSU crystals, the acute inflam-
matory response to these crystals (gout flare), and tophus for-
mation. A gout flare typically presents as an acutely inflamed 
and extremely painful lower limb joint. The symptoms peak 
over the first 24 h and then gradually resolve over the next 
10–14 days. Flares are usually recurrent, and the patient is 
well in between flares. In some patients with prolonged hyper-
uricemia, tophi can develop both in the joint and non-articular 
tissues; these are collections of MSU crystals surrounded by 
a chronic inflammatory granulomatous response.2  
As described earlier, it is well established from genome-
wide association studies that ABCG2 variants are associ-
ated with elevated serum urate concentrations. However, 
as pointed out above, these studies show that the influence 
of ABCG2 variants on serum urate is lower than SLC2A9 
variants. In contrast, ABCG2 variants are more strongly 
associated with risk of gout than SLC2A9; Köttgen et al4 
reported ORs for gout of 1.73, P=1.7×10−39 for ABCG2 and 
1.56, P=1.9×10−31, for SLC2A9. In a more recent analysis,86 
ABCG2 was associated with an increased risk of gout; com-
pared with asymptomatic hyperuricemia controls, the OR 
for gout was 1.83, P=2.6×10−14, in European people, and was 
2.35, P=3.9×10−5, in Polynesian people. In contrast, SLC2A9 
variants were not associated with increased risk of gout when 
compared with asymptomatic hyperuricemia controls.86 
These are intriguing findings that suggest a role for ABCG2 
in developing gout once hyperuricemia is established. They 
do, however, require replication in other sample sets.
ABCG2 variants have also been associated with topha-
ceous disease in people with gout. In a Taiwanese study of 
people with gout, 141K was associated with tophi in both 
Han and Aboriginal Taiwanese populations (OR 1.51 and 
1.50, respectively, for the 141K allele, pooled OR 1.55, 
P=7.8×10−5).69 Recently, a New Zealand study of people 
with gout has reported that risk alleles for two ABCG2 
SNPs, Q141K and rs10011796, were associated with tophi 
(compared with gout patients without tophi), with effects 
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observed in participants of Western Polynesian (Samoan, 
Tongan, Niuean, and Tokelaun) ancestry (OR for rs2231142 
1.71, P=0.017 and for rs10011796, 3.76, P=0.002) but not in 
people of other ancestries (European and Eastern Polynesian 
[NZ Māori, Cook Island Māori]).87 The ABCG2 associations 
persisted in Western Polynesian people even after account-
ing for serum urate and disease duration in the regression 
models. Given that only two studies have thus far associated 
ABCG2 with tophus in gout, further studies are required to 
substantiate this relationship.
These genetic data suggest a role of ABCG2 in the 
presentation of gout that is, at least in part, independent 
of hyperuricemia. Supporting this, cyclosporine inhibits 
ABCG2 in vitro,88 hyperuricemia and gout can be induced by 
cyclosporine,89 and there is an interaction between cyclospo-
rine and colchicine90 (colchicine is commonly used to treat 
gout attacks and is able to correct the dysfunctional internal-
ization of ABCG2 141K36). Collectively, these observations 
suggest that ABCG2 may be influenced by off-target effects 
of cyclosporine. It is possible that ABCG2 influences other 
checkpoints, such as MSU crystal formation or the inflam-
matory response to these crystals. Although the mechanisms 
of MSU crystal formation are incompletely understood, 
it is conceivable that ABCG2 variants lead to preferential 
transport of urate into the joint (or reduced efflux out of the 
joint), resulting in higher saturating urate concentrations and 
MSU crystal formation.  
Mechanistic aspects of ABCG2 in 
inflammation
A schematic diagram of the role of ABCG2 in inflammation 
is shown in Figure 3B. NLRP3 (NBD, leucine-rich family 
[NLR], pyrin containing 3) inflammasome activation leading 
to mature interleukin (IL)-1β release through caspase-1 is a 
key step in the initiation of the acute gout flare.91 An initial 
signal (signal 1) is required to stimulate the expression of pro-
IL-1β and inflammasome components.92 Signal 1 includes 
Toll-like receptor-4 (TLR4) and TLR2 ligands, as well as 
unsaturated long-chain free fatty acids,93,94 and can be inhib-
ited by omega-3 fatty acids and HDL-cholesterol.95,96 MSU 
crystals act as signal 2, inducing NLRP3 inflammasome com-
plex oligomerization and activation of caspase-1.91 Genes in 
this system have been associated with gout. A variant in TLR4, 
that likely influences TLR4 expression, has been associated 
with gout in two studies.97,98 Two SNPs in NLRP3-related 
genes have been associated with gout.99–101 The first one is a 
nonsense variation in the caspase recruitment domain-con-
taining protein 8 (CARD8, rs2043211), a negative regulator 
of the NLRP3 inflammasome. One of the studies also found 
a multiplicative interaction between this SNP and an IL-1β 
polymorphism (rs1143623)101 consistent with a pathogenic 
model whereby greater inflammasome activity from reduced 
CARD8 expression, combined with higher levels of pre-IL-1β 
expression, leads to increased production of mature IL-1β and 
an amplified immune response. Furthermore, the PPARGC1B 
SNP associated with gout (rs45529037) upregulates the 
expression of NLRP3 and IL-1β.52 
The role of ABCG2 in regulating inflammation has been 
described in nonarticular cells. In HEK293 cells cultured with 
H
2
O
2
, ABCG2 inhibited reactive oxygen species generation, 
enhanced anti-oxidant capacity of the cells, and protected 
cells from reactive oxygen species-induced toxicity.102 This 
may be mediated by the role of ABCG2 in exporting urate, 
an established pro-oxidant in the intracellular setting103 by 
mechanisms that include promotion of mitochondrial dys-
function.104 In animals, ABCG2 also inhibited NF-κB and the 
expression of the inflammatory gene IL-8 induced by reactive 
oxygen species.102 In rheumatoid arthritis, a chronic autoim-
mune inflammatory arthritis, ABCG2 is highly expressed in 
the intimal lining layer and on macrophages and endothelial 
cells in the synovial sub-lining layer.105 The synovium is also a 
very important tissue in gouty arthritis. In several cell culture 
systems, the expression and function of ABCG2 is reduced 
when stimulated with pro-inflammatory cytokines.106–108 Col-
lectively, these results suggest both a suppressive effect of 
ABCG2 on pro-inflammatory signaling pathways and that 
ABCG2 is itself a target of pro-inflammatory cytokines, 
where its expression and activity is suppressed. To date, the 
influence of ABCG2 variants on the inflammatory response 
to MSU crystals has not been reported, although genetic and 
other data suggest a role for the 141K variant in promoting 
gout once hyperuricemia is established (see the ‘ABCG2: a 
regulator of gouty inflammation?’ section).
ABCG2 and autophagy
In addition to its effects through increased serum urate con-
centration and the inflammatory responses described earlier, 
ABCG2 has been reported to play a role in autophagy. In a 
study by Ding et al,109 ABCG2 overexpressing cell lines were 
more resistant to stressors such as nutrient deprivation due 
to increased autophagy. The authors observed more degrada-
tion of autophagy receptor p62 and increased accumulation 
of LC3-II, a protein essential for autophagosome formation 
and function. Knockdown of ABCG2 in these cells subse-
quently abolished these effects.109 It was shown previously 
that effective autophagy is essential in acute gouty arthritis 
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to clear mitochondria that have been damaged by MSU 
crystals. This prevents the release of mitochondrial DNA 
and the production of reactive oxygen species, which can 
activate the NLRP3 inflammasome.110,111 When autophagy 
is not effective, p62 accumulates, causing nuclear factor 
E2-related factor 2 (Nrf2), a transcription factor involved in 
oxidative stress responses, to be released from its repressor, 
kelch-like ECH-associated protein 1 (keap-1), and translocate 
to the nucleus. Previously, Nrf2 has been shown to induce 
transcription of heme oxygenase-1 and superoxide dismutase, 
which can in turn also activate the NLRP3 inflammasome.112 
Finally, ABCG2 expression has been shown to be upregulated 
by Nrf2, which promotes cancer stem cell survival.46 Taken 
together, ABCG2 plays a role in autophagy and its expres-
sion is induced through Nrf2. Decreased or a lack of ABCG2 
function could therefore induce or prolong NLRP3 inflamma-
some activation in acute gout through defective autophagy of 
damaged mitochondria in response to MSU crystals. 
ABCG2 as a drug target
Restoring the expression and function of ABCG2 molecules 
that harbor detrimental genetic polymorphisms may be an 
important next step to limit urate levels and inflammatory 
responses. Recently, several papers have shown that histone 
deacetylase (HDAC) inhibitors can restore the function of 
the 141K ABCG2 variant. Woodward et al demonstrated 
that the HDAC inhibitor 4-phenylbutyrate restores traffick-
ing and dimer expression of 141K ABCG2.32 Basseville et 
al showed that several different HDAC inhibitors, as well 
as colchicine, inhibit targeting of 141K ABCG2 to the 
aggresome and promote relocalization on the cell surface.36 
Colchicine is an anti-inflammatory agent that acts by inhibit-
ing microtubule polymerization through binding to tubulin. 
This suggests that HDAC inhibitors, as does colchicine, 
inhibit trafficking of ABCG2 to the aggresome along micro-
tubules. Finally, in addition to restoring surface localization 
of 141K ABCG2, the HDAC inhibitor romidepsin was shown 
to increase gene transcription of ABCG2 by activating the 
aryl hydrocarbon pathway.113 Recently, small molecules 
that are effective at rescuing the trafficking, abundance, 
and function of the 141K variant protein have been found. 
The compounds VRT-325 and 4a, both from the corrector 
class of molecules found in efforts to rescue mutant CFTR 
protein, are effective rescue agents for mutant ABCG2 as 
well.32 These results should encourage further research into 
the use of less toxic small molecules than HDAC inhibitors 
to restore defective ABCG2 function in patients with the 
141K polymorphism.
ABCG2 and allopurinol response
Allopurinol is the most commonly used urate-lowering 
therapy for people with gout. It is rapidly metabolized to 
oxypurinol which is responsible for the majority of the urate-
lowering effect through the inhibition of xanthine oxidase. 
Despite widespread use of allopurinol, many people fail 
to achieve the recommended target serum urate of <0.36 
mmol/L. For example, in the Febuxostat versus Allopurinol 
Controlled Trial, only 21% of those receiving allopurinol 300 
mg daily achieved the primary endpoint of the last three serum 
urates being ≤0.36 mmol/L.114 Although poor adherence and 
restricted dosing based on kidney function are frequently 
associated with failure to reach target serum urate, genes 
encoding the enzymes involved in the metabolism, mechanism 
of action, and excretion of allopurinol may also have a role.115 
Most studies related to the pharmacogenetics of allopu-
rinol have focused on adverse events rather than predicting 
efficacy.116 However, two recent studies have highlighted a 
potential role for ABCG2 in allopurinol response. A significant 
association between ABCG2 141K and reduced allopurinol 
response was initially identified in a genome-wide association 
study.67 However, the definition of response used in this study 
was allopurinol-related change in serum urate, and there was 
only assessment of adherence with allopurinol using adminis-
trative data. A subsequent study, in which poor response was 
defined as serum urate ≥0.36 mmol/L despite allopurinol >300 
mg daily, and with adherence confirmed by plasma oxypurinol 
concentrations, replicated the finding with 141K conferring 
a significantly increased risk of poor response to allopurinol 
(OR 2.71 (1.70–4.48), P=6.0×10−5).117 This effect remained 
significant after adjustment for various variables that influ-
ence serum urate and allopurinol response including age, sex, 
BMI, ethnicity, eGFR, diuretic use, and serum urate off urate-
lowering therapy. The association between ABCG2 Q141K 
and allopurinol response is a very interesting observation that 
should be further replicated in further studies.
The mechanism by which ABCG2 modulates allopuri-
nol response is not clear. Wen et al67 reported ABCG2 to be 
an efficient allopurinol and oxypurinol efflux pump. HEK 
293 cells transfected with 141K had significantly impaired 
ABCG2 function leading to intracellular accumulation of 
allopurinol and oxypurinol.67 These authors suggested that 
the ABCG2 141K variant might impair allopurinol response 
by increasing allopurinol and oxypurinol concentrations in 
renal tubular cells and decreasing concentration in the tubule 
fluid, thereby reducing the inhibition of uric acid influx 
pumps within the kidney. However, this theory is unproven, 
and modeling the complexity of the relative contribution 
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of reabsorbed allopurinol118 versus nonsecreted allopurinol 
is extremely difficult; therefore, in vivo experiments are 
required to further explore this possible mechanism.  
ABCG2 and chronic kidney disease
It is clinically established that chronic kidney disease is 
a cause of hyperuricemia and gout. However, the physi-
ological response to disrupted renal uric acid handling in 
kidney disease is a question of clinical interest. Bhatnagar 
et al119 addressed this question by evaluating the strength of 
genetic association with urate of variants in a suite of genes 
encoding uric acid transporters (including SCL2A9, ABCG2, 
SLC17A1-A3, and SLC22A11-A12) in 3,598 individuals with 
chronic kidney disease. In contrast to the situation in healthy 
individuals where SLC2A9 has the strongest magnitude of 
association on serum urate levels (0.37 mg/dL increase in 
urate per risk allele compared with 0.22 mg/dL for ABCG2 
in sex-adjusted analysis),4 each ABCG2 risk allele increased 
serum urate by 0.68 mg/dL in people of European ancestry, 
compared with 0.30 mg/dL for SLC2A9 in sex-adjusted 
analysis.119 Although this finding requires replication, it 
does suggest that the extra-renal (gut) urate handling of 
ABCG2 necessarily compensates in renal injury.119 This is 
consistent with the observation, in nephrectomized rats, of 
increased gut expression of ABCG2 and maintenance of 
normal serum urate concentration.120 Bhatnagar et al119 evoke 
the “remote sensing and signaling” hypothesis whereby the 
action of multi-specific SLC and ABC transporters is critical 
in disrupted homeostasis resulting from organ injury.121 The 
hypothesis posits that the transporters cooperate in sensing 
and controlling fluctuations in important substances, with 
the ABC (and SLC) transporters facilitating interorgan 
communication through small molecules,121 including those 
important in oxidant status such as urate.122 One specific 
example of this is the ability of ABCG2 to transport and 
transfer heme, through an extracellular loop, to albumin.123 
In a study of fructose-induced hyperuricemia in humans, 
the urate-increasing 141K allele was associated with a 
lower increase in serum urate but greater increase in frac-
tional excretion of uric acid when compared with the 141Q 
allele,78 consistent with the previously reported ROL type 
of hyperuricemia. Supporting ABCG2 as a “remote sensor 
and signaller,” the 141K allele was associated with a lower 
glucose response to the fructose load.78 Whether or not the 
urate and glucose effects are related is unclear; however, the 
remote sensing hypothesis could relate to differential ATP 
utilization by the 141Q and 141K alleles given that the 141K 
variant has significantly reduced ATPase activity.32
Hyperuricemia predicts reduced renal function and chronic 
kidney disease, independent of measured confounders, in 
observational studies.124 However, whether or not urate is 
causal of reduced renal function is unresolved. Mendelian ran-
domization studies, in which urate-associated genetic variants 
inherited at conception are used as an un-confounded proxy for 
exposure to urate,125 suggest that urate is not causal of reduced 
renal function in healthy people126 but could promote progres-
sion of declining renal function in chronic kidney disease.127 
Based on the observation in mice that uric acid may compete 
with toxins as an efflux substrate of ABCG2, Dankers et al 
postulate that, in the kidney, hyperuricemia promotes reduced 
renal ABCG2-mediated secretion of toxic molecules.128
Conclusion
The ABCG2 transporter is an important molecule in urate 
excretion. Decreased ABCG2 expression and function due 
to genetic polymorphisms leads to both ROL hyperuricemia 
and RUE hyperuricemia. The most extensively studied genetic 
variant is Q141K. Besides significantly increasing serum urate 
concentration, the 141K ABCG2 variant has also been associ-
ated with acute gout, tophaceous gout, and poor allopurinol 
response. In addition, 141K-induced hyperuricemia may lead to 
excessive inflammatory responses and decreased ABCG2 func-
tion may cause defective autophagy. All of these effects warrant 
further research to the restoration of 141K ABCG2 function 
and surface expression, for example, by small molecules.
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